- Home
- FRSH vs VKTX Comparison
FRSH vs VKTX Comparison
Compare FRSH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSH
- VKTX
- Stock Information
- Founded
- FRSH 2010
- VKTX 2012
- Country
- FRSH United States
- VKTX United States
- Employees
- FRSH N/A
- VKTX N/A
- Industry
- FRSH EDP Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FRSH Technology
- VKTX Health Care
- Exchange
- FRSH Nasdaq
- VKTX Nasdaq
- Market Cap
- FRSH 4.5B
- VKTX 4.7B
- IPO Year
- FRSH 2021
- VKTX 2015
- Fundamental
- Price
- FRSH $17.44
- VKTX $32.65
- Analyst Decision
- FRSH Buy
- VKTX Strong Buy
- Analyst Count
- FRSH 14
- VKTX 12
- Target Price
- FRSH $19.36
- VKTX $106.75
- AVG Volume (30 Days)
- FRSH 3.2M
- VKTX 4.1M
- Earning Date
- FRSH 02-11-2025
- VKTX 02-05-2025
- Dividend Yield
- FRSH N/A
- VKTX N/A
- EPS Growth
- FRSH N/A
- VKTX N/A
- EPS
- FRSH N/A
- VKTX N/A
- Revenue
- FRSH $685,960,000.00
- VKTX N/A
- Revenue This Year
- FRSH $22.34
- VKTX N/A
- Revenue Next Year
- FRSH $13.82
- VKTX N/A
- P/E Ratio
- FRSH N/A
- VKTX N/A
- Revenue Growth
- FRSH 20.45
- VKTX N/A
- 52 Week Low
- FRSH $10.81
- VKTX $20.75
- 52 Week High
- FRSH $23.30
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- FRSH 65.85
- VKTX 25.74
- Support Level
- FRSH $15.29
- VKTX $32.51
- Resistance Level
- FRSH $16.96
- VKTX $43.55
- Average True Range (ATR)
- FRSH 0.53
- VKTX 2.05
- MACD
- FRSH 0.12
- VKTX -0.44
- Stochastic Oscillator
- FRSH 93.09
- VKTX 1.27
About FRSH Freshworks Inc.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.